Chari Nikhil S, Pinaire Nicole L, Thorpe Lynnelle, Medeiros L Jeffrey, Routbort Mark J, McDonnell Timothy J
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Apoptosis. 2009 Apr;14(4):336-47. doi: 10.1007/s10495-009-0327-9.
The molecular subversion of cell death is acknowledged as a principal contributor to the development and progression of cancer. The p53 tumor suppressor protein is among the most commonly altered proteins in human cancer. The p53 protein mediates critical functions within cells including the response to genotoxic stress, differentiation, senescence, and cell death. Loss of p53 function can result in enhanced rates of cell proliferation, resistance to cell death stimuli, genomic instability, and metastasis. The community of cancer scientists is now in possession of a vast repository of information regarding the frequency, specific mechanisms, and clinical context of cell death deregulation in cancer. This information has enabled the design of therapeutic agents to target proteins, including p53. The feasibility and impact of targeting cell death signaling proteins has been established in preclinical models of human cancer. The appropriate application of these targeted agents is now being established in clinical trials.
细胞死亡的分子颠覆被认为是癌症发生和发展的主要促成因素。p53肿瘤抑制蛋白是人类癌症中最常发生改变的蛋白之一。p53蛋白介导细胞内的关键功能,包括对基因毒性应激的反应、分化、衰老和细胞死亡。p53功能丧失可导致细胞增殖速率提高、对细胞死亡刺激的抗性、基因组不稳定和转移。癌症科学家群体现在拥有大量关于癌症中细胞死亡失调的频率、具体机制和临床背景的信息库。这些信息使得能够设计针对包括p53在内的蛋白质的治疗药物。在人类癌症的临床前模型中已经确定了靶向细胞死亡信号蛋白的可行性和影响。目前正在临床试验中确定这些靶向药物的适当应用。